|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Lung ADCA harbouring BRAF mutations are commonly non-V600E.
|
30591192 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations.
|
31440061 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF mutation (V600E) was seen in one de novo-type case and two CIA-type cases, but none of these cases had MMR protein loss.
|
31282116 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.
|
29248665 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients (<i>n</i> = 59) from 24 centres were included: 57.6% men; mean age: 64.5 ± 14.5 years; 82% with a performance status of 0-1 at diagnosis; smoking status: 40.3% current, 32.6% former; 93% with adenocarcinoma histology; 75% stage iv; 78% with V600E mutations; 2 with <i>EGFR</i> and 2 with <i>ALK</i> co-mutations.
|
30464690 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IHC cytoplasmic expression of BRAF V600E (VE1) protein was found in two of 95 cases: one case of adenocarcinoma NOS (one of three; 33%) and one case of carcinoma ex pleomorphic adenoma (one of five; 20%).
|
27682157 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
None of the MMRD small bowel adenocarcinomas harbored the BRAF V600E mutation, whereas 60% of MMRD colorectal carcinomas were positive for BRAF V600E with concurrent loss of MLH1 and PMS2 expression.
|
27258561 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma.
|
27001432 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Median age was 63 years (range 42-85); gender was balanced; 14 (40%) were never smokers; all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had other mutations; one of them had a concomitant KRAS mutation.
|
26200454 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
From our patients and literature search, we found that BRAF-V600E mutations occur predominantly in female smokers with adenocarcinomas.
|
26066373 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAF(V600E) mutations, and 4 were non-BRAF(V600E) mutations.
|
25273224 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Somatic BRAF mutations have been reported in 1-4% of non-small cell lung cancer (NSCLC), primarily in adenocarcinomas with the BRAF (V600E) mutation in about 50% of the cases.
|
24888229 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
CIMP(+) was detected in 27 of 99 (27.3%) duodenal adenocarcinomas and was associated with MSI (P = 0.011) and MLH1 methylation (P < 0.001), but not with KRAS mutations (P = 0.114), as compared with CIMP(-) tumors.No BRAF V600E mutation was detected.
|
22825585 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of the 259 proximal colon adenocarcinomas analyzed for mismatch repair protein abnormalities and/or MSI, 181 proximal colonic adenocarcinomas demonstrated proficient DNA mismatch repair using either MSI PCR (n=78), mismatch repair protein immunohistochemistry (n=91), or both MSI PCR and mismatch repair immunohistochemistry (n=12); these were tested for the BRAF V600E mutation and KRAS mutations.
|
22314188 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and CpG island methylation phenotype-positive status are similar in signet ring cell carcinoma and mucinous adenocarcinoma but more frequent when compared with conventional adenocarcinoma.
|
22522845 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed 29 gallbladder carcinomas (9 papillary and 20 nonpapillary adenocarcinomas), 16 adenomas (6 pyloric, 3 intestinal, 3 biliary, 3 mixed pyloric-biliary, and 1 mixed pyloric-intestinal), and 5 cases of high-grade dysplasia for activating missense mutations in KRAS codons 12 and 13 and BRAF V600E mutations.
|
21307665 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The V600E mutation of the B-RAF gene was analyzed using allele-specific polymerase chain reaction in 79 archival prostatic adenocarcinomas (pT1aG1 to pT3cG3, median Gleason score 6); exons 11 and 15 were sequenced.
|
16413100 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In exon 15, one BRAF mutation (1796 thymine to adenine; V599E) was found in nonsmoking woman with well-differentiated adenocarcinoma.
|
16376942 |
2006 |